Description

Product Description

Bevacizumab (CAS 216974-75-3) is a recombinant humanized monoclonal IgG1 antibody targeting VEGF-A, a critical regulator of angiogenesis and vascular permeability. By binding VEGF-A isoforms, Bevacizumab prevents their interaction with VEGFR-1 and VEGFR-2 receptors, blocking downstream signaling pathways such as PI3K/Akt, MAPK/ERK, and PLCγ. This inhibition reduces endothelial cell proliferation, migration, tube formation, and survival.

The sterile solution format allows direct application in endothelial cell culture, 3D vascular organoids, microfluidic angiogenesis models, and tumor microenvironment assays. Researchers can use Bevacizumab to dissect VEGF-dependent mechanisms, evaluate anti-angiogenic therapeutics, and model vascular normalization in preclinical studies. Its high purity and GMP-grade production ensure reproducible outcomes across laboratories, making it suitable for bulk research, OEM projects, and high-throughput experimentation.

Bevacizumab’s structural integrity, including proper glycosylation and Fc region configuration, ensures stable VEGF-A binding, minimal aggregation, and preserved biological activity. The solution has been validated for low endotoxin levels, sterility, and consistent bioactivity, supporting long-term research workflows. Its applications include tumor angiogenesis inhibition, endothelial permeability modulation, vascular sprouting studies, and organoid vascular network formation.

Product Specifications

Mechanism of Action

Bevacizumab binds VEGF-A isoforms with high affinity, preventing interaction with VEGFR-1 and VEGFR-2 on endothelial cells. This blockade inhibits receptor dimerization and downstream phosphorylation events, suppressing pathways that control cell proliferation, migration, tube formation, and survival. The antibody also reduces vascular permeability by stabilizing endothelial tight junctions, and it impairs sprouting angiogenesis in both 2D and 3D in vitro models.

In tumor microenvironment research, Bevacizumab reduces neovascularization, normalizes vessel structure, and modulates extracellular matrix interactions. Its sterility and high purity allow reproducible applications in organoids, co-culture systems, and microfluidic models. Mechanistic studies demonstrate its efficacy in inhibiting PI3K/Akt and MAPK/ERK signaling, making it a robust tool for angiogenesis research, drug screening, and translational preclinical studies.

Side Effects

As a research-use-only reagent, Bevacizumab may exhibit cell-line-specific cytotoxicity or off-target effects when used at high concentrations. In vitro, it can induce endothelial growth arrest, reduce migration, or alter tube formation in sensitive cell types. Handling precautions include using sterile techniques, avoiding repeated freeze-thaw cycles, and minimizing light exposure. Laboratory personnel should follow biosafety guidelines for recombinant antibodies.

Bevacizumab is designed for experimental research; effects observed are limited to cellular and tissue models. Care should be taken to accurately titrate doses to avoid confounding experimental outcomes. Stability under recommended storage ensures consistent functional activity, reducing variability in long-term studies.

Keywords

Bevacizumab, CAS 216974-75-3, sterile solution, VEGF-A inhibitor, high-purity antibody, research reagent, endothelial assays, angiogenesis studies, organoid vascularization, tumor microenvironment, GMP OEM, bulk supply, recombinant monoclonal antibody, small-molecule supplier, China chemical manufacturer, high-purity chemical, laboratory reagent, preclinical research, bulk production, research-grade antibody

Shipping Guarantee

Bevacizumab sterile solution is shipped under cold chain conditions with ice packs or dry ice, ensuring stable temperature control throughout transit. Packaging is leak-proof and sterile to maintain product integrity. Global tracking and insurance are provided, ensuring reliable delivery for research laboratories worldwide. Bulk orders and OEM shipments are managed with stringent temperature monitoring to prevent degradation.

Trade Assurance

Each batch of Bevacizumab is verified for ≥99% purity via HPLC-SEC and bioactivity assays. Certificates of Analysis (CoA) are provided with each shipment. The GMP-compliant production process guarantees batch consistency. Returns and exchanges are supported for QC-related issues, ensuring reliable supply for research and preclinical studies.

Payment Support

Payments are accepted via PayPal, T/T, international bank transfer, credit card, USDT, Bitcoin, and Ethereum. Encrypted verification ensures secure transactions for bulk and OEM orders. Global support for multiple currencies is available for research institutions and commercial laboratories.

Disclaimer

Bevacizumab is intended for laboratory research only. It is not for human or veterinary use. Follow all biosafety regulations when handling, and use appropriate sterile techniques. The product is provided as GMP-compliant research reagent only, not as a therapeutic agent.

References

• PubChem: https://pubchem.ncbi.nlm.nih.gov/

• ChEMBL: https://www.ebi.ac.uk/chembl/

• DrugBank: https://go.drugbank.com/

• PubMed: https://pubmed.ncbi.nlm.nih.gov/

• IUPHAR/BPS: https://www.guidetopharmacology.org/